U.S. IT Stock News

Lyft, Inc. (NasdaqGS:LYFT) has received preliminary approval to operate in Israel, alongside other ride hailing platforms. The approval is pending full consent from Israel's parliament before commercial services can formally launch. The move signals a potential expansion for Lyft beyond its current core US market footprint. Lyft runs an app based ride hailing platform that connects riders with drivers, with its business still largely centered in the US. The progress in Israel comes at a...

If you are wondering whether Agios Pharmaceuticals at around US$28.66 is offering value or just noise, this article will walk through what the current price might really mean. The stock has returned 3.1% over the last 7 days and 16.6% over the last 30 days, while the 1 year return sits at negative 19.0%. This can catch the eye of investors thinking about changing risk and return trade offs. Recent coverage of Agios has focused on its position within the pharmaceuticals and biotech space and...

Earlier in January 2026, Axsome Therapeutics announced that the first patient had been dosed in its FORWARD Phase 3 trial of AXS-14 (esreboxetine) for fibromyalgia, a randomized withdrawal study following a 12-week open-label treatment period. This progress, combined with preliminary unaudited guidance pointing to strong year-over-year product revenue growth in the fourth quarter and full year 2025, underscores how Axsome is advancing both its late-stage pipeline and its commercial portfolio...

Earlier this week, Oscar Health reported quarterly results showing revenue growth of 23.3% year on year but missing analysts’ estimates, while also raising its full-year operating income guidance above market forecasts. A separate disclosure that institutional investor Blue Square Asset Management exited its entire Oscar Health position added a fresh layer of complexity to how investors interpret the company’s outlook. Next, we’ll examine how the stronger operating income guidance amid an...

Why Bright Horizons Family Solutions (BFAM) is on investors’ radar today Bright Horizons Family Solutions (BFAM) has drawn fresh attention after recent share price moves, with the stock showing mixed short term performance despite positive reported revenue and net income growth on an annual basis. See our latest analysis for Bright Horizons Family Solutions. At a share price of $93.95, Bright Horizons Family Solutions has seen short term share price pressure, with a 30 day share price return...

Federal Signal, a provider of safety and emergency equipment to government, municipal, and industrial customers, has recently reported five-year annual revenue growth of 12.3% and earnings per share growth of 27.9%, alongside a 12-month sales outlook calling for 15.4% higher revenue. This combination of solid historical revenue gains and a robust forward sales pipeline highlights how Federal Signal is capitalizing on demand for critical safety and emergency infrastructure. Next, we'll...

Earlier in January 2026, Uber Technologies, Inc. and The Kroger Co. launched nearly 2,700 Kroger Family of Companies stores on the Uber Eats, Uber, and Postmates apps, giving households nationwide same-day access to full grocery assortments across multiple Kroger banners. This large-scale integration not only broadens Uber’s delivery footprint but also illustrates how partnerships with major grocers can deepen customer engagement beyond restaurant orders. Next, we’ll examine how Uber’s...

Brown-Forman (BF.B) is back in focus as investors position ahead of its upcoming Q3 earnings report, weighing expectations for softer results against the company’s premiumization push and recent U.S. distribution and cost restructuring efforts. See our latest analysis for Brown-Forman. Brown-Forman’s recent 1-month share price return of 4.84% and year to date share price return of 6.85% suggest some momentum is building again, even as the 1-year total shareholder return of 13.18% and 5-year...

Intro General Dynamics (GD) is back in focus after securing a US$988 million contract to modernize the U.S. Navy's C5ISR networks, a move that feeds directly into its defense technology backlog. See our latest analysis for General Dynamics. At a share price of US$365.83, General Dynamics has seen a 6.5% year to date share price return and a 38.9% total shareholder return over the past year, with recent defense contract wins helping sustain that momentum. If this Navy contract has you looking...

If you are wondering whether Amentum Holdings is priced attractively right now, the recent share moves give you some useful clues to work with. The stock last closed at US$35.56, with returns of 2.8% over the past week, 20.7% over the past month, 16.7% year to date and 63.9% over the past year, which has likely shifted how some investors view both its potential and its risks. Recent news around Amentum has focused on its position as a listed government and commercial services provider, as...

In January 2026, law firm Kahn Swick & Foti, LLC launched an investigation into Crocs, Inc. over potential fiduciary breaches tied to alleged under‑disclosure of HEYDUDE brand underperformance and inventory issues, following a securities class action lawsuit. This development places Crocs’ corporate governance and disclosure practices under closer scrutiny, raising questions about how management assessed and communicated acquisition risks to shareholders. Next, we’ll examine how this...

Beam Therapeutics (BEAM) is back in focus after securing regulatory alignment with the FDA on an accelerated approval pathway for its BEAM-302 program targeting alpha-1 antitrypsin deficiency, sharpening attention on upcoming data. See our latest analysis for Beam Therapeutics. The regulatory alignment on BEAM-302 has arrived alongside a strong 1-month share price return of 23.37% and a 1-year total shareholder return of 30.32%. However, the 3-year and 5-year total shareholder returns of...

If you are wondering whether Stanley Black & Decker at around US$83.73 is a bargain or just fairly priced, it helps to line up how the current share price compares with the value implied by different methods. The stock has had a mixed return profile, with a 12.2% gain over the last 30 days and a 9.5% return year to date, alongside a 1% decline over the past year and a 45.1% decline over five years, which can change how investors think about both upside and risk. Recent coverage has focused...

Live Oak Bancshares (LOB) just wrapped up FY 2025 with fourth quarter total revenue of US$139.9 million and basic EPS of US$0.96, while trailing twelve month revenue came in at US$480.8 million with EPS of US$2.25. Over recent periods, the company has seen quarterly revenue move from US$93.3 million in Q4 2024 to US$139.9 million in Q4 2025, with quarterly EPS shifting from US$0.22 to US$0.96 over the same span. This sets up a results season where investors are focused on how sustainably the...

Heritage Financial (HFWA) has wrapped up FY 2025 with fourth quarter revenue of US$67.2 million and basic EPS of US$0.65, while trailing twelve month revenue and EPS came in at US$244.2 million and US$1.99 respectively, supported by trailing net income of US$67.5 million. Over the past year, revenue has moved from US$210.6 million to US$244.2 million on a trailing basis, with EPS rising from US$1.26 to US$1.99. This sets the stage for a discussion that is very much about earnings power and...

Arm Holdings (NasdaqGS:ARM) has launched a new Physical AI division focused on robotics, autonomous vehicles, and other real world AI applications. The company is working with partners including SoftBank and Broadcom to develop AI specific chips aimed at next generation computing. These moves represent a significant restructuring of Arm's operations and a clearer focus on AI hardware ecosystems. Arm designs chip architectures that sit at the core of many smartphones, data center servers,...

Recent performance snapshot for Pfizer (PFE) Pfizer (PFE) has moved quietly higher in recent months, with a 1-month return of 4.9% and a past 3-month return of 5.4%, while its 1-year total return sits at 7.6%. See our latest analysis for Pfizer. With the share price at $26.10 and a steady 30 day share price return of 4.9%, recent gains contrast with a 3 year total shareholder return decline of 29.3%, suggesting improving sentiment relative to a weaker long term picture. If Pfizer has you...

Bath & Body Works (BBWI) is in focus after a new class action lawsuit linked to earlier earnings misses, guidance cuts, and management’s admission that recent growth initiatives did not expand its customer base. See our latest analysis for Bath & Body Works. The new lawsuit arrives after a weak stretch for investors, with a 1-year total shareholder return decline of about 37% and a 3-year total shareholder return decline of about 46%, even though the 30-day share price return of 17.3% and...

Byline Bancorp recently reported its fourth-quarter 2025 results, with revenue rising 11.8% year on year and non-GAAP EPS of $0.76, both ahead of analyst expectations. Management also highlighted progress in deepening its commercial presence and expanding its customer base, suggesting operational initiatives are reinforcing the bank’s earnings profile. We’ll now examine how Byline Bancorp’s stronger-than-expected earnings, supported by growth in commercial relationships, shape the company’s...

American Electric Power’s board recently declared a regular quarterly cash dividend of US$0.95 per share, payable on March 10, 2026, to shareholders of record as of February 10, 2026, marking the company’s 463rd consecutive quarterly common stock cash dividend. Alongside this dividend affirmation, AEP’s US$2.65 billion plan with Bloom Energy to build a Wyoming fuel cell power facility, backed by a 20‑year offtake agreement, highlights its push into newer power generation technologies while...

Diamondback Energy, Inc. recently reported that it received lower realized prices for oil and natural gas in the fourth quarter of 2025, reflecting a weaker crude and gas market that also affected many peers across the sector. Analysts now expect a profit decline of 33.8% for the upcoming fourth-quarter earnings release, highlighting how Diamondback’s focus on debt reduction and cash returns, rather than expanding output, can amplify the earnings impact of softer commodity pricing. Next, we...

Event context and recent share performance With no single headline event driving attention today, SharkNinja (SN) is drawing interest as investors weigh its recent share performance against current financial figures and its role in household appliances. See our latest analysis for SharkNinja. SharkNinja’s share price, now at $123.97, has seen a 30 day share price return of 9.16% and a 90 day share price return of 28.25%. The 1 year total shareholder return of 11.20% suggests momentum has...

RLI (RLI) closed out FY 2025 with fourth quarter revenue of US$465.7 million and basic EPS of US$0.99, alongside net income of US$91.2 million and a combined ratio of 82.6%, giving investors a clean snapshot of both top line scale and underwriting performance. Over recent periods, the company has seen quarterly revenue move from US$439.1 million in Q4 2024 to US$465.7 million in Q4 2025, while basic EPS shifted from US$0.44 to US$0.99, supported by trailing twelve month EPS of US$4.37 on...

Novo Nordisk (NYSE:NVO) has expanded its partnership with Aspect Biosystems to advance cell-based treatments for diabetes. The company has launched an oral version of Wegovy, the first FDA approved oral GLP-1 pill for obesity. These moves broaden Novo Nordisk's diabetes pipeline and strengthen its position in obesity treatments with a non injectable option. Novo Nordisk, trading at $62.23, sits at the center of two closely watched areas in healthcare: diabetes and obesity care. The stock is...